McKesson Co. (NYSE:MCK) Shares Sold by Peoples Bank KS

Peoples Bank KS decreased its holdings in shares of McKesson Co. (NYSE:MCKFree Report) by 1.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,975 shares of the company’s stock after selling 20 shares during the quarter. Peoples Bank KS’s holdings in McKesson were worth $1,060,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Douglass Winthrop Advisors LLC boosted its holdings in McKesson by 1.4% in the fourth quarter. Douglass Winthrop Advisors LLC now owns 1,512 shares of the company’s stock valued at $700,000 after acquiring an additional 21 shares during the last quarter. Addison Advisors LLC raised its position in McKesson by 7.9% in the fourth quarter. Addison Advisors LLC now owns 299 shares of the company’s stock valued at $138,000 after purchasing an additional 22 shares during the period. Evergreen Wealth Solutions LLC raised its position in McKesson by 1.2% in the fourth quarter. Evergreen Wealth Solutions LLC now owns 1,931 shares of the company’s stock valued at $894,000 after purchasing an additional 22 shares during the period. Keystone Financial Services increased its position in shares of McKesson by 2.1% during the fourth quarter. Keystone Financial Services now owns 1,192 shares of the company’s stock worth $552,000 after acquiring an additional 24 shares during the last quarter. Finally, Carolinas Wealth Consulting LLC increased its position in shares of McKesson by 42.9% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 80 shares of the company’s stock worth $37,000 after acquiring an additional 24 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. StockNews.com lowered McKesson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Robert W. Baird lifted their price target on McKesson from $603.00 to $671.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 8th. Morgan Stanley lifted their price target on McKesson from $522.00 to $548.00 and gave the stock an “overweight” rating in a research note on Monday, April 15th. Leerink Partnrs reiterated an “outperform” rating on shares of McKesson in a research note on Monday, February 26th. Finally, UBS Group lifted their price target on McKesson from $620.00 to $630.00 and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $571.47.

View Our Latest Research Report on McKesson

Insider Buying and Selling at McKesson

In other McKesson news, EVP Leann B. Smith sold 600 shares of the company’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $585.53, for a total value of $351,318.00. Following the transaction, the executive vice president now owns 2,022 shares of the company’s stock, valued at $1,183,941.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Brian S. Tyler sold 3,753 shares of the stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $574.41, for a total value of $2,155,760.73. Following the completion of the sale, the chief executive officer now owns 89,845 shares in the company, valued at $51,607,866.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Leann B. Smith sold 600 shares of the stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $585.53, for a total value of $351,318.00. Following the completion of the sale, the executive vice president now owns 2,022 shares of the company’s stock, valued at approximately $1,183,941.66. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 25,814 shares of company stock valued at $14,511,649. Corporate insiders own 0.21% of the company’s stock.

McKesson Trading Up 0.9 %

NYSE:MCK traded up $5.48 during midday trading on Tuesday, hitting $602.93. 446,414 shares of the stock were exchanged, compared to its average volume of 705,227. McKesson Co. has a one year low of $395.30 and a one year high of $604.15. The company has a market capitalization of $78.37 billion, a price-to-earnings ratio of 26.94, a P/E/G ratio of 1.38 and a beta of 0.47. The business has a 50-day moving average price of $553.85 and a two-hundred day moving average price of $517.58.

McKesson (NYSE:MCKGet Free Report) last announced its earnings results on Tuesday, May 7th. The company reported $6.18 EPS for the quarter, missing the consensus estimate of $6.34 by ($0.16). McKesson had a negative return on equity of 245.88% and a net margin of 0.97%. The firm had revenue of $76.36 billion for the quarter, compared to the consensus estimate of $79.32 billion. During the same period in the previous year, the firm earned $7.19 EPS. McKesson’s revenue for the quarter was up 10.8% on a year-over-year basis. Sell-side analysts forecast that McKesson Co. will post 31.54 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Monday, June 3rd will be issued a $0.62 dividend. The ex-dividend date is Monday, June 3rd. This represents a $2.48 annualized dividend and a dividend yield of 0.41%. McKesson’s dividend payout ratio is currently 11.08%.

About McKesson

(Free Report)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

Featured Stories

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCKFree Report).

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.